Gaurav Munj 2022-03-04T06:42:16+00:00 CREATING SHAREHOLDER VALUE Site - Investor Relations Nav Overview Press Releases Events and Presentations Financial Filings Stock Information Corporate Governance Contact Upcoming and Recent Events Corporate Presentation SEC Filings Stock Quote & Chart Historical Lookup Governance Documents Committees Biohaven is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. Latest Press Releases December 16, 2024 Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates December 6, 2024 Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting View All Press Releases View All Events September 23, 2024 at 8:30 AM EDT Biohaven Topline Pivotal Trial Results for Troriluzole in Spinocerebellar Ataxia Listen to webcast May 29, 2024 Biohaven R&D Day at Yale School of Management May 31, 2023 Biohaven R&D Day at Yale School of Management View All Events View All BIOHAVEN EVENTSCORPORATE PRESENTATION LETTER FROM THE CHAIRMAN & CEO VIDEOS play video INTERVIEW WITH CEO VLAD CORIC M.D. ON CNBC’S FAST MONEY x play video Interview with CEO Vlad Coric M.D. on CNBC’s Mad Money x play video Diseases related to glutamate dysregulation x
Biohaven is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. Latest Press Releases December 16, 2024 Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates December 6, 2024 Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting View All Press Releases View All Events September 23, 2024 at 8:30 AM EDT Biohaven Topline Pivotal Trial Results for Troriluzole in Spinocerebellar Ataxia Listen to webcast May 29, 2024 Biohaven R&D Day at Yale School of Management May 31, 2023 Biohaven R&D Day at Yale School of Management View All Events View All BIOHAVEN EVENTSCORPORATE PRESENTATION LETTER FROM THE CHAIRMAN & CEO VIDEOS play video INTERVIEW WITH CEO VLAD CORIC M.D. ON CNBC’S FAST MONEY x play video Interview with CEO Vlad Coric M.D. on CNBC’s Mad Money x play video Diseases related to glutamate dysregulation x
December 16, 2024 Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates
December 6, 2024 Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting
September 23, 2024 at 8:30 AM EDT Biohaven Topline Pivotal Trial Results for Troriluzole in Spinocerebellar Ataxia Listen to webcast